http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#Head http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#assertion http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#provenance http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#pubinfo http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#assertion http://purl.obolibrary.org/obo/MONDO_0002046 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/MONDO_0002046 http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://go.drugbank.com/drugs/DB00181 http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#association http://www.w3.org/2000/01/rdf-schema#label Only a few medications are available for the treatment of alcohol use disorders (AUDs). Areas covered: This paper discusses approved AUD medications, including the opioid antagonists naltrexone and nalmefene (the latter is licensed for reduction of alcohol consumption only), the putative glutamate receptor antagonist acamprosate and the aldehyde dehydrogenase inhibitor disulfiram. It also covers off-label medications of interest, including topiramate, gabapentin, ondansetron, varenicline, baclofen, sodium oxybate and antidepressants. http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#association https://w3id.org/biolink/vocab/has_population_context http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#cohort http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#association https://w3id.org/biolink/vocab/publications https://pubmed.ncbi.nlm.nih.gov/28658981/ http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#association https://w3id.org/biolink/vocab/relation https://w3id.org/um/neurodkg/OffLabelIndication http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#cohort http://www.w3.org/2000/01/rdf-schema#label Adults http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#cohort https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Cohort https://go.drugbank.com/drugs/DB00181 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#provenance http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-7641-6446 http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#pubinfo http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#sig http://purl.org/nanopub/x/hasSignature N2XsExtuSmDqhsNyTCiQWOKqjpX7taazpFSQ99SWIAbaHj6jaicozOpU3De70jiapB2C44dxRltVljWre2CYuHWaTpJy4ddi2C3GPWJy8Dn4dVS+VwujvHRTEyfs1GiqCakDLzkAig6jOYw7NmIEeQTi6+2lX5kGTB7lWV/c4Bo= http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M http://purl.org/dc/terms/created 2021-08-25T19:56:26.456+02:00 http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M http://purl.org/dc/terms/creator https://orcid.org/0000-0002-7641-6446 http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M http://purl.org/nanopub/x/supersedes http://purl.org/np/RABKQoWBPe2xHiJO1OWK6-thNeldFTB3JfKDn0FT2dBSY http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAjpBMlw3owYhJUBo3DtsuDlXsNAJ8cnGeWAutDVjuAuI http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAZdZj78B6nKrP1Q00oFzsK07u7WdiY3sToz-H-H2nSgg